US EditionBiaCure Therapies Awarded SBIR Phase I Grant to Advance Development of High-Frequency Energy Technology for the Treatment of Onychomycosis
- On May 15, 2025, BiaCure Therapies from Pewaukee, Wisconsin announced receiving a $2.6 million SBIR Phase I grant from the NIH.
- The grant supports developing BiaCure’s proprietary high-frequency energy therapy system to treat onychomycosis, a chronic nail fungal infection affecting over 35 million Americans.
- BiaCure intends to use the funding over three years to develop and validate BiaPulse, a device delivering targeted therapy via a patient-friendly applicator aiming for a short-course, non-invasive mycological cure.
- Laura King, CEO of BiaCure Therapies, stated that receiving the SBIR grant affirms the company's scientific direction, and the funding will support clinical trials with dermatology and podiatry specialists to assess the effectiveness of fungal elimination.
- The grant advances BiaCure’s mission to provide an effective alternative for patients who failed or cannot tolerate oral antifungal medications while improving treatment efficacy and patient experience.
Insights by Ground AI
Does this summary seem wrong?
31 Articles
31 Articles
All
Left
Center
13
Right
1
Temple Daily Telegram+30 Reposted by 30 other sources
BiaCure Therapies Awarded SBIR Phase I Grant to Advance Development of High-Frequency Energy Technology for the Treatment of Onychomycosis
PEWAUKEE, Wis., May 15, 2025 /PRNewswire/ -- BiaCure Therapies, an emerging innovator in non-invasive medical technology, today announced it has been awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Institutes of Health (NIH) in the…
Coverage Details
Total News Sources31
Leaning Left0Leaning Right1Center13Last UpdatedBias Distribution93% Center
Bias Distribution
- 93% of the sources are Center
93% Center
C 93%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
